Qrons Announces U.S. Patent Office Grants Dartmouth College 3D Printing Patent Forming Basis of License Agreement with Qrons

Rhea-AI Summary

Qrons Inc. (OTCQB:QRON) announced that the USPTO granted U.S. Patent No. 10,954,315 to Dartmouth College, covering 3-D printing materials. This patent results from Qrons' collaboration with Professor Chenfeng Ke since July 2018, focused on developing 3D printable hydrogels for its stem cell-based treatments for traumatic brain injuries. The exclusive license from Dartmouth allows Qrons to leverage these advancements in its biotech innovations. CEO Jonah Meer emphasized the importance of this step in enhancing Qrons' technological foundation.

Positive

• Issuance of U.S. Patent No. 10,954,315 enhances Qrons' technological capabilities.
• Exclusive license agreement with Dartmouth College allows for commercialization of advanced 3D printing materials.

Negative

• None.

NEW YORK, NY / ACCESSWIRE / April 22, 2021 / Qrons Inc. (OTCQB:QRON), an innovative biotechnology company developing next generation treatments for unmet neuronal diseases, using tissue engineering, stem cells and machine learning synergic technologies is proud to report that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,954,315 to the Trustees of Dartmouth College which is directed to mechanically interlocked ,molecules-based materials for 3-D printing. The patents inventors are Professor Chenfeng Ke, a member of Qrons Scientific Advisory Board and Qianming Lin, Professor Ke's assistant.

Since July 2018, Qrons has conducted research with Professor Ke under a Sponsored Research Agreement with Dartmouth to develop innovative 3D printable hydrogels, biocompatible advanced materials as a component of its stem cell-based traumatic brain injury treatment. In October 2019, Qrons entered into an Intellectual Property License Agreement with Dartmouth for an exclusive world-wide license of intellectual property related to 3D printable materials in the fields of human and animal health. This patent grant is the culmination of that process.

Professor Ke explained " I am really excited about the issuance of the patent. I think it is an important step forward for the development of our hydrogels. I think this issued patent, along with several pending patent applications forms the foundation of our technology. "

Jonah Meer, CEO of Qrons, commented " Ido Merfeld, our co-founder who worked closely with Dr. Ke, and I commend Professor Ke for his brilliance and diligence in obtaining this important patent. We are proud to have been part of the process and hope to engage in future projects with Professor Ke and his talented team at Dartmouth in furtherance of our development model that includes collaborating with leading academic institutions."

About Dartmouth College
Founded in 1769, Dartmouth College is a member of the Ivy League and consistently ranks among the world's greatest academic institutions. Dartmouth has forged a singular identity for combining its deep commitment to outstanding undergraduate liberal arts and graduate education with distinguished research and scholarship in the Arts & Sciences and its three leading professional schools - the Geisel School of Medicine, Thayer School of Engineering, and the Tuck School of Business.

About Qrons Inc.
Headquartered in New York City, with research conducted in Israel, Qrons is an innovative biotechnology company dedicated to developing biotech products, treatments and technologies to combat neuronal diseases an enormous social and economic burden on society. Qrons' approach is to seek to engage in strategic arrangements with companies and institutions that are developing breakthrough technologies in the fields of artificial intelligence , machine learning , molecular biology, stem cells and tissue engineering, for deployment in the fight against neuronal diseases. Our search is focused on researchers based in Israel, a country which is world-renowned for biotech innovations. Please visit https://www.qrons.com.

Forward-Looking Statement
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations, to attract and retain qualified professionals, technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission.

Contacts:
Qrons Inc.
Jonah Meer
Chief Executive Officer
212-945-2080

SOURCE: Qrons Inc.

View source version on accesswire.com:
https://www.accesswire.com/641432/Qrons-Announces-US-Patent-Office-Grants-Dartmouth-College-3D-Printing-Patent-Forming-Basis-of-License-Agreement-with-Qrons

FAQ

What recent patent was granted to Qrons Inc. related to 3D printing?

The USPTO granted U.S. Patent No. 10,954,315 to Dartmouth College, which Qrons is licensed to use for developing 3D printable materials.

How does the new patent impact Qrons Inc.'s operations?

The patent supports Qrons' development of advanced materials for its stem cell-based traumatic brain injury treatment.

What is the significance of the patent issued to Dartmouth College for Qrons?

It forms the basis for Qrons' strategic research collaborations and enhances its product development capabilities.

When did Qrons begin its partnership with Dartmouth College?

Qrons started its partnership with Dartmouth in July 2018 under a Sponsored Research Agreement.

What technologies does Qrons focus on for treating neuronal diseases?

Qrons focuses on tissue engineering, stem cells, and machine learning in its treatment developments.